title: The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells.
abstract: Angiogenesis is now recognized as a crucial process in tumor development, including hepatocellular carcinoma (HCC). Since HCC is known as a hypervascular tumor, anti-angiogenesis is a promising approach to inhibit the HCC development. Trientine dihydrochloride (trientine) is used in clinical practice as an alternative copper (Cu)-chelating agent for patients with Wilson's disease of penicillamine intolerance. In our study, we examined the effect of Cu-chelating agents on tumor development and angiogenesis in the murine HCC xenograft model. Although both trientine and penicillamine in the drinking water suppressed the tumor development, trientine exerted a more potent inhibitory effect than penicillamine. In combination with a Cu-deficient diet, both trientine and penicillamine almost abolished the HCC development. Trientine treatment resulted in a marked suppression of neovascularization and increase of apoptosis in the tumor, whereas tumor cell proliferation itself was not altered. In vitro studies also exhibited that trientine is not cytotoxic for the tumor cells. On the other hand, it significantly suppressed the endothelial cell proliferation. These results suggested that Cu plays a pivotal role in tumor development and angiogenesis in the murine HCC cells, and Cu-chelators, especially trientine, could inhibit angiogenesis and enhance apoptosis in the tumor with consequent suppression of the tumor growth in vivo. Since trientine is already used in clinical practice without any serious side effects as compared to penicillamine, it may be an effective new strategy for future HCC therapy.
authors.affiliation: Third Department of Internal Medicine, Nara Medical University, Nara, Japan.
authors.forename: J
authors.initials: J
authors.lastname: Yoshii
authors.forename: H
authors.initials: H
authors.lastname: Yoshiji
authors.forename: S
authors.initials: S
authors.lastname: Kuriyama
authors.forename: Y
authors.initials: Y
authors.lastname: Ikenaka
authors.forename: R
authors.initials: R
authors.lastname: Noguchi
authors.forename: H
authors.initials: H
authors.lastname: Okuda
authors.forename: H
authors.initials: H
authors.lastname: Tsujinoue
authors.forename: T
authors.initials: T
authors.lastname: Nakatani
authors.forename: H
authors.initials: H
authors.lastname: Kishida
authors.forename: D
authors.initials: D
authors.lastname: Nakae
authors.forename: D E
authors.initials: DE
authors.lastname: Gomez
authors.forename: M S
authors.initials: MS
authors.lastname: De Lorenzo
authors.forename: A M
authors.initials: AM
authors.lastname: Tejera
authors.forename: H
authors.initials: H
authors.lastname: Fukui
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002614:Chelating Agents / Q000627:therapeutic use*; D003300:Copper / Q000502:physiology*; D005260:Female; D008114:Liver Neoplasms, Experimental / Q000098:blood supply / Q000517:prevention & control*; D051379:Mice; D008807:Mice, Inbred BALB C; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D010396:Penicillamine / Q000627:therapeutic use; D014266:Trientine / Q000627:therapeutic use*
chemical_list: D002614:Chelating Agents; D003300:Copper; D010396:Penicillamine; D014266:Trientine